Rebecca Brown, MD, discusses how the NCCN guideline inclusion of brigatinib is changing clinical practice for NF2-related schwannomatosis.
Spotlighting the Evolution of NF2-Related Schwannomatosis Management Strategies
Experts spotlight the evolution of treatment strategies for patients with NF2-related schwannomatosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5